Monitor Q3 FY2027 revenue against the $640M-$680M guidance range and watch for order booking recovery in non-life sciences as Section 338 tariff modifications take effect. The Fixed Cost Transformation Program's $65M-$75M annualized savings target is key to margin recovery, but lower volumes are temporarily offsetting benefits.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $17.57entry
- T+1 · 12d ago −1.42%α +2.99% · $17.32
- T+5 · 6d ago +0.46%α +1.37% · $17.65
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
ATS reported Q2 FY2027 revenue of $665.8M, down 8.6% YoY, and a net loss of $5.0M vs net income of $33.6M a year ago. Management withdrew its prior guidance for modest revenue growth and 50-75 bps margin expansion in FY2027, citing temporary delays in non-life sciences bookings from tariff uncertainty, and guided Q3 FY2027 revenue of $640M-$680M. Order bookings rose 12.7% YoY to $827M, led by life sciences, but adjusted EBITDA margin contracted 211 bps to 12.1%.
Key Financial Metrics
Key Facts
- Q2 FY2027 revenue $665.8M, down 8.6% YoY from $728.5M
- Net loss of $5.0M vs net income of $33.6M a year ago
- Adjusted basic EPS $0.27 vs $0.45 a year ago, down 40%
- Management withdrew FY2027 guidance for modest revenue growth and 50-75 bps margin expansion
- Q3 FY2027 revenue guidance of $640M-$680M
- Order bookings $827M, up 12.7% YoY; life sciences bookings at second-highest quarter on record
- Order backlog $2,009M, down 2.9% YoY
- Adjusted EBITDA margin 12.1% vs 14.2% a year ago, down 211 bps
- Restructuring costs of $21.3M in Q2, half related to Fixed Cost Transformation Program
- Section 338 tariffs caused customer delays in packaging automation equipment; modifications announced late October expected to reduce impact
- Net debt to pro forma adjusted EBITDA at 3.1x, above the 2.0-3.0x target range
- Company repurchased 2,244,461 shares for $61.3M under NCIB during the quarter
- Disclosure controls and procedures not effective due to a material weakness in ICFR
Financial Impact
Revenue decline of $62.7M YoY (8.6%), net loss swing of $38.6M, adjusted EBITDA down $23.0M (22.2%)
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Life Sciences | $355.8M | -5.0% |
| Industrial Consumer | $136.4M | -23.5% |
| Food Beverage | $99.6M | -20.2% |
| Energy | $74.0M | +45.1% |
Risk Factors
- Continued tariff uncertainty and customer capital expenditure delays could further pressure revenue and margins
- Net debt leverage at 3.1x above target range limits financial flexibility
- Material weakness in internal controls over financial reporting remains unremediated
- Restructuring execution risk and potential for additional workforce reductions
- Lower GLP-1-related activity and portfolio repositioning in industrial consumer may persist
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001394832-26-000028 |
| Document: ats-financialstatementsxfy.htm | 0001394832-26-000028 |
| Document: ats-pressreleasexfy27q2.htm | 0001394832-26-000028 |
| Document: form6k-fy27q2.htm | 0001394832-26-000028 |
| Document: q2fy27-atsceocertification.htm | 0001394832-26-000028 |
| Document: q2fy27-atscfocertification.htm | 0001394832-26-000028 |
| Document: 0001394832-26-000028-index-headers.html | 0001394832-26-000028 |
| Document: 0001394832-26-000028-index.html | 0001394832-26-000028 |
| Document: 0001394832-26-000028.txt | 0001394832-26-000028 |
| Earnings Context (Synthetic; results releases only) | 0001394832-26-000028 |
Track record
13 reports on ATS
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $16.97 to $17.50 Now $17.96 +5.83% ▲ +3.12% +0.53% vs SPY
- Nov 4, 202612d ago 6-K Bearish 6/10 Viewing Entry $17.57 to $17.65 Now $17.96 −2.22% ▼ −0.46% −1.37% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $18.97 to $17.74 Now $17.96 −5.32% ▼ −6.48% −6.56% vs SPY
- Sep 3, 202610w ago 6-K Neutral 2/10 Entry $19.57 to $19.20 Now $17.96 −8.23% ▼ −1.89% −0.74% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 5/10 Entry $19.73 to $19.59 Now $17.96 +8.97% ▲ +0.71% +0.66% vs SPY
- Aug 7, 202614w ago 6-K Neutral 2/10 Entry $21.13 to $20.31 Now $17.96 −15.00% ▼ −3.88% −4.28% vs SPY
- Aug 6, 202614w ago 6-K Bearish 7/10 Entry $20.53 to $20.13 Now $17.96 +12.52% ▲ +1.95% +3.16% vs SPY
- Jul 27, 202616w ago 6-K Neutral 2/10 Entry $26.59 to $27.24 Now $17.96 −32.46% ▲ +2.44% +1.37% vs SPY
- Jul 2, 202619w ago 6-K Neutral 2/10 Entry $27.68 to $27.74 Now $17.96 −35.12% ▲ +0.22% −0.71% vs SPY
- Jun 11, 202622w ago 6-K Neutral 2/10 Entry $26.88 to $28.32 Now $17.96 −33.18% ▲ +5.36% +4.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers